Skip to main content
Erschienen in: Immunologic Research 4/2017

16.05.2017 | Original Article

Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer

verfasst von: Mao Lin, Shu-Zhen Liang, Xiao-Hua Wang, Ying-Qing Liang, Ming-Jie Zhang, Li-Zhi Niu, Ji-Bing Chen, Hai-Bo Li, Ke-Cheng Xu

Erschienen in: Immunologic Research | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

In this study, the safety and clinical efficacy of cryosurgery combined with allogenic NK cell immunotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) were evaluated. From July 2016 to March 2017, we enrolled 60 patients who met the enrollment criteria and divided them into two groups: (1) the simple cryoablation group (n = 30) and (2) the cryoablation combined with allogenic NK cell group (n = 30). The changes in immune function, quality of life, and clinical response were evaluated. We found that allogenic NK cells combined with cryosurgical treatment for advanced NSCLC have a synergistic effect, which not only enhancing the immune function of patients, improving the quality of life, and significantly increasing the response rate (RR) and disease control rate (DCR) compared to cryoablation group. This study is the first clinical trial of allogenic NK cells combined with cryosurgery for the treatment of advanced NSCLC and preliminaily its safety and efficacy.
Literatur
2.
Zurück zum Zitat Chen Z, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46.CrossRefPubMed Chen Z, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46.CrossRefPubMed
3.
Zurück zum Zitat Yang L, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 2013;62:65–73.CrossRefPubMed Yang L, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 2013;62:65–73.CrossRefPubMed
4.
Zurück zum Zitat Zhao M, et al. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med. 2014;7:1403–7.PubMedPubMedCentral Zhao M, et al. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med. 2014;7:1403–7.PubMedPubMedCentral
5.
Zurück zum Zitat Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer--the smoke clears. N Engl J Med. 2005;352:2640–2.CrossRefPubMed Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer--the smoke clears. N Engl J Med. 2005;352:2640–2.CrossRefPubMed
6.
Zurück zum Zitat Keller SM, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern cooperative oncology group. N Engl J Med. 2000;343:1217–22.CrossRefPubMed Keller SM, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern cooperative oncology group. N Engl J Med. 2000;343:1217–22.CrossRefPubMed
7.
Zurück zum Zitat Felip E, et al. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments. Curr Opin Oncol. 2013;25:115–20.CrossRefPubMed Felip E, et al. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments. Curr Opin Oncol. 2013;25:115–20.CrossRefPubMed
8.
Zurück zum Zitat Sharma A, et al. How I do it: radiofrequency ablation and cryoablation of lung tumors. J Thorac Imaging. 2011;26:162–74.CrossRefPubMed Sharma A, et al. How I do it: radiofrequency ablation and cryoablation of lung tumors. J Thorac Imaging. 2011;26:162–74.CrossRefPubMed
9.
Zurück zum Zitat Maiwand MO, et al. The application of cryosurgery in the treatment of lung cancer. Cryobiology. 2004;48:55–61.CrossRefPubMed Maiwand MO, et al. The application of cryosurgery in the treatment of lung cancer. Cryobiology. 2004;48:55–61.CrossRefPubMed
10.
Zurück zum Zitat Kornprat P, et al. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg. 2007;142:1087–92.CrossRefPubMed Kornprat P, et al. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg. 2007;142:1087–92.CrossRefPubMed
11.
Zurück zum Zitat Levy D, et al. Current state of urological cryosurgery: prostate and kidney. BJU Int. 2010;105:590–600.CrossRefPubMed Levy D, et al. Current state of urological cryosurgery: prostate and kidney. BJU Int. 2010;105:590–600.CrossRefPubMed
12.
Zurück zum Zitat Izumi Y, et al. The acute effects of transthoracic cryoablation on normal lung evaluated in a porcine model. Ann Thorac Surg. 2005;79:318–22. discussion 22CrossRefPubMed Izumi Y, et al. The acute effects of transthoracic cryoablation on normal lung evaluated in a porcine model. Ann Thorac Surg. 2005;79:318–22. discussion 22CrossRefPubMed
14.
Zurück zum Zitat Xu KC, et al. Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma. World J Gastroenterol. 2003;9:2686–9.CrossRefPubMedPubMedCentral Xu KC, et al. Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma. World J Gastroenterol. 2003;9:2686–9.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Orlacchio A, et al. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. Cardiovasc Intervent Radiol. 2008;31:587–94.CrossRefPubMed Orlacchio A, et al. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. Cardiovasc Intervent Radiol. 2008;31:587–94.CrossRefPubMed
16.
Zurück zum Zitat Aerts JG, et al. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013;73:2381–8.CrossRefPubMed Aerts JG, et al. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013;73:2381–8.CrossRefPubMed
17.
Zurück zum Zitat Lv M, et al. miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancer. Mol Cancer Ther. 2014;13:3152–62.CrossRefPubMed Lv M, et al. miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancer. Mol Cancer Ther. 2014;13:3152–62.CrossRefPubMed
19.
Zurück zum Zitat Thomas A, et al. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13:e301–10.CrossRefPubMed Thomas A, et al. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13:e301–10.CrossRefPubMed
20.
Zurück zum Zitat Hasegawa T, et al. Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol. 2014;2:685–94.PubMedPubMedCentral Hasegawa T, et al. Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol. 2014;2:685–94.PubMedPubMedCentral
21.
22.
23.
Zurück zum Zitat Zhao Y, et al. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-beta signaling pathway. Onco Targets Ther. 2015;8:1553–9.PubMedPubMedCentral Zhao Y, et al. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-beta signaling pathway. Onco Targets Ther. 2015;8:1553–9.PubMedPubMedCentral
25.
Zurück zum Zitat Wang D, et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 2014;14:251.CrossRefPubMedPubMedCentral Wang D, et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 2014;14:251.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Li JJ, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 2012;35:189–95.CrossRefPubMed Li JJ, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 2012;35:189–95.CrossRefPubMed
27.
Zurück zum Zitat Pan K, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res. 2014;20:3003–11.CrossRefPubMed Pan K, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res. 2014;20:3003–11.CrossRefPubMed
28.
Zurück zum Zitat Pan K, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20:4305–11.CrossRefPubMed Pan K, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20:4305–11.CrossRefPubMed
29.
Zurück zum Zitat Ljunggren HG, et al. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329–39.CrossRefPubMed Ljunggren HG, et al. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329–39.CrossRefPubMed
31.
Zurück zum Zitat Niu L, et al. Combination of cryosurgery and iodine-125 seeds brachytherapy for lung cancer. J Thorac Dis. 2012;4:504–7.PubMedPubMedCentral Niu L, et al. Combination of cryosurgery and iodine-125 seeds brachytherapy for lung cancer. J Thorac Dis. 2012;4:504–7.PubMedPubMedCentral
33.
Zurück zum Zitat Witt CS, et al. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang. 2006;90:10–20.CrossRefPubMed Witt CS, et al. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang. 2006;90:10–20.CrossRefPubMed
34.
Zurück zum Zitat Forte P, et al. HLA-Cw4 expression on porcine endothelial cells reduces cytotoxicity and adhesion mediated by CD158a+ human NK cells. Xenotransplantation. 2009;16:19–26.CrossRefPubMed Forte P, et al. HLA-Cw4 expression on porcine endothelial cells reduces cytotoxicity and adhesion mediated by CD158a+ human NK cells. Xenotransplantation. 2009;16:19–26.CrossRefPubMed
35.
Zurück zum Zitat Kunert K, et al. KIR/HLA ligand incompatibility in kidney transplantation. Transplantation. 2007;84:1527–33.CrossRefPubMed Kunert K, et al. KIR/HLA ligand incompatibility in kidney transplantation. Transplantation. 2007;84:1527–33.CrossRefPubMed
36.
37.
Zurück zum Zitat Imai C, et al. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376–83.CrossRefPubMedPubMedCentral Imai C, et al. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376–83.CrossRefPubMedPubMedCentral
38.
39.
Zurück zum Zitat Goldberg SN, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005;16:765–78.CrossRefPubMed Goldberg SN, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005;16:765–78.CrossRefPubMed
40.
Zurück zum Zitat Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
41.
42.
Zurück zum Zitat Asimakopoulos G, et al. Cryosurgery for malignant endobronchial tumors: analysis of outcome. Chest. 2005;127:2007–14.CrossRefPubMed Asimakopoulos G, et al. Cryosurgery for malignant endobronchial tumors: analysis of outcome. Chest. 2005;127:2007–14.CrossRefPubMed
43.
Zurück zum Zitat Yamauchi Y, et al. Percutaneous cryoablation for pulmonary nodules in the residual lung after pneumonectomy: report of two cases. Chest. 2011;140:1633–7.CrossRefPubMed Yamauchi Y, et al. Percutaneous cryoablation for pulmonary nodules in the residual lung after pneumonectomy: report of two cases. Chest. 2011;140:1633–7.CrossRefPubMed
44.
Zurück zum Zitat Ljunggren HG, et al. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237–44.CrossRefPubMed Ljunggren HG, et al. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237–44.CrossRefPubMed
45.
Zurück zum Zitat Mikelsaar AV, et al. Epitope of titin A-band-specific monoclonal antibody Tit1 5 H1.1 is highly conserved in several Fn3 domains of the titin molecule. Centriole staining in human, mouse and zebrafish cells. Cell Div. 2012;7:21.CrossRefPubMedPubMedCentral Mikelsaar AV, et al. Epitope of titin A-band-specific monoclonal antibody Tit1 5 H1.1 is highly conserved in several Fn3 domains of the titin molecule. Centriole staining in human, mouse and zebrafish cells. Cell Div. 2012;7:21.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Burns LJ, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 2003;32:177–86.CrossRefPubMed Burns LJ, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 2003;32:177–86.CrossRefPubMed
47.
Zurück zum Zitat de Magalhaes-Silverman M, et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother. 2000;23:154–60.CrossRef de Magalhaes-Silverman M, et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother. 2000;23:154–60.CrossRef
48.
Zurück zum Zitat Iliopoulou EG, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1781–9.CrossRefPubMed Iliopoulou EG, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1781–9.CrossRefPubMed
49.
Zurück zum Zitat Re F, et al. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer. 2006;107:640–8.CrossRefPubMed Re F, et al. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer. 2006;107:640–8.CrossRefPubMed
50.
Zurück zum Zitat Geller MA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98–107.CrossRefPubMed Geller MA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98–107.CrossRefPubMed
Metadaten
Titel
Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer
verfasst von
Mao Lin
Shu-Zhen Liang
Xiao-Hua Wang
Ying-Qing Liang
Ming-Jie Zhang
Li-Zhi Niu
Ji-Bing Chen
Hai-Bo Li
Ke-Cheng Xu
Publikationsdatum
16.05.2017
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 4/2017
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-017-8927-x

Weitere Artikel der Ausgabe 4/2017

Immunologic Research 4/2017 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.